(*) Equal contribution

19.  Blum R. Stepping inside the realm of epigenetic modifiers. Biomol Concepts. 2015 May 1;6(2):119-136 

18.  Vitanza NA, Zaky W, Blum R, Meyer JA, Wang J, Bhatla T, Morrison DJ, Raetz EA, Carroll WL. Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance. Pediatr Blood Cancer. 2014 Oct; 61(10):1779-85 

17. Blum R. Activation of muscle enhancers by MyoD and epigenetic modifiers.
J Cell Biochem. 2014 Jun 6; 115(11): 1855-67

16. Jones CL, Bhatla T, Blum RWang J, Paugh SW, Wen X, 
Bourgeois W, Bitterman DS, Raetz EA, Morrison DJ, Teachey DT, Evans WE, Garabedian MJ and Carroll WL. Loss of TBL1XR1 Disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model.
J Biol Chem. 2014 July 25; 289(30):20502-15

15. Cheng J, Blum R,  Bowman C, Hu D, Shilatifard A, Shen S, Dynlacht BD. A role for H3K4 monomethylation in gene repression and partitioning of chromatin readers.
14. Blum R, Kloog Y. Metabolism addiction in pancreatic cancer.
13. Blum R, Dynlacht BD. The role of MyoD1 and histone modifications in the activation of muscle enhancers.
Epigenetics. 2013 Aug 1; 8(8): 778-784

12. Blum R, Vethantham V, Bowman C, Rudnicki MA, Dynlacht BD. Genome-wide identification of enhancers in skeletal muscle: The role of MyoD1.
Genes Dev. 2012 Dec 15; 26(24):2763-2779.

11. Vazquez-Cintron EJ, Monu NR, Burns JC,
Blum R, Chen G, Lopez P, Ma J, Radoja S, Frey AB. Protocadherin-18 is a novel differentiation marker and an Inhibitory signaling receptor for CD8+ effector memory T cells.
PLoS ONE 2012; 7(5):e36101.

10. Asp P*, Blum R*, Vethantham V, Parisi F, Micsinai M, Cheng J, Bowman C, Kluger Y, Dynlacht BD. Genome-wide remodeling of the epigenetic landscape during myogenic differentiation.
Proc Natl Acad Sci. 2011 May 31;108(22):E149-58.

9. Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiong X, Kamb A, Wesche H, Marshall L, Cutler G, Wang X, Zavadil J, Moscatelli D, Wilson EL. Molecular signatures of the primitive prostate stem cell niche reveal novel mesenchymal-epithelial signaling pathways.
PLoS ONE 2010;5(9):e13024.

8. Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiong X, Kamb A, Wesche H, Marshall L, Cutler G, Wang X, Zavadil J, Moscatelli D, Wilson EL. Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer.
PLoS ONE 2009;4(5):e5722.

7. Blum R, Cox AD, Kloog Y. Inhibitors of chronically active Ras: potential for treatment of human malignancies.
Recent Patents on Anti-Cancer Drug Discovery 2008 Jan 1;3(17): 31-47.

6. Blum R, Elkon R, Yaari S, Zundelevich A, Jacob-Hirsch J, Rechavi G, Shamir R, Kloog Y. Gene expression signature of human cancer cell lines treated with the Ras inhibitor salirasib (FTS).
Cancer Res. 2007 Apr 1;67(7):3320-33281.

5. Erlich S, Tal-Or P, Liebling R, Blum R, Karunagaran D, Kloog Y, Pinkas-Kramarski R. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells.
Biochem Pharmacol. 2006 Aug 14;72(4):427-36.

4. Blum R, Jacob-Hirsch J, Rechavi G, Kloog Y. Suppression of survivin expression in glioblastoma by the Ras inhibitor trans-farnesylthiosalicylic acid (FTS) promotes caspase-dependent apoptosis.
Mol Cancer Ther. 2006 Sept;5(9):2337-47.

3. Blum R, Nakdimon I, Goldberg L, Elkon R, Shamir R, Rechavi G, Kloog Y. E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition.
Int. J. Cancer 2006 Feb 22;119(3), 527–538.

2. Blum R and Kloog Y. Tailoring Ras-pathway – inhibitor combinations for cancer therapy.
Drug Resist Updat. 2005 Dec 12;8(6):369-380.

1. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death.
Cancer Res. 2005 Feb 1;65(3):999-1006.